Neoadjuvant therapy using PD-1 inhibitor plus chemotherapy with different intervals between chemotherapy cycles for locally advanced gastric or gastroesophageal junction cancer: A randomized phase 2 study

被引：0
|
作者：
Gao, Quanli
Zhao, Lingdi
Zhao, Weijie
Wang, Zibing
Qin, Peng
Jiang, Zhiqiang
Huang, Jinxi
Zhang, Bin
Li, Zhimeng
Fu, Qiang
Zhao, Yuzhou
Ren, Yingkun
Shang, Chuang
Wan, Xiangbin
Gao, Yang
Xu, Yongchao
Yuan, Long
Lu, Chaomin
Li, Zhi
机构：
[1] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Dept Immunol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[3] Henan Canc Hosp, Zhengzhou, Peoples R China
[4] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[5] Zhengzhou Univ, Surg Oncol, Henan Canc Hosp, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[6] Zhengzhou Univ, Dept Surg Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4064
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial
    Yang, Yingchi
    Pang, Kai
    Lin, Guole
    Liu, Xinzhi
    Gao, Jiale
    Zhou, Jiaolin
    Xu, Lai
    Gao, Zhidong
    Wu, Yingchao
    Li, Ang
    Han, Jiagang
    Wu, Guoju
    Wang, Xin
    Li, Fei
    Ye, Yingjiang
    Zhang, Jie
    Chen, Guangyong
    Wang, Hao
    Kong, Yuanyuan
    Wu, Aiwen
    Xiao, Yi
    Yao, Hongwei
    Zhang, Zhongtao
    NATURE MEDICINE, 2025, 31 (02) : 449 - 456
  • [42] Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis
    Liu, Bo-Wei
    Shang, Qi-Xing
    Yang, Yu-Shang
    Chen, Long-Qi
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [43] MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer
    Janjigian, Yelena Y.
    Van Cutsem, Eric
    Muro, Kei
    Wainberg, Zev
    Al-Batran, Salah-Eddin
    Hyung, Woo Jin
    Molena, Daniela
    Marcovitz, Michelle
    Ruscica, Dario
    Robbins, Scott H.
    Negro, Alejandra
    Tabernero, Josep
    FUTURE ONCOLOGY, 2022, 18 (20) : 2465 - 2473
  • [44] Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial
    Shu-Qiang Yuan
    Run-Cong Nie
    Ying Jin
    Cheng-Cai Liang
    Yuan-Fang Li
    Rui Jian
    Xiao-Wei Sun
    Ying-Bo Chen
    Wen-Long Guan
    Zi-Xian Wang
    Hai-Bo Qiu
    Wei Wang
    Shi Chen
    Dong-Sheng Zhang
    Yi-Hong Ling
    Shao-Yan Xi
    Mu-Yan Cai
    Chun-Yu Huang
    Qiu-Xia Yang
    Zhi-Min Liu
    Yuan-Xiang Guan
    Yong-Ming Chen
    Ji-Bin Li
    Xiong-Wen Tang
    Jun-Sheng Peng
    Zhi-Wei Zhou
    Rui-Hua Xu
    Feng Wang
    Nature Medicine, 2024, 30 : 552 - 559
  • [45] Atezolizumab and trastuzumab plus chemotherapy in patients with HER2+locally advanced resectable gastric cancer or adenocarcinoma of the gastroesophageal junction: A multicenter, randomized, open-label phase II study.
    Peng, Zhi
    Zhang, Xiaotian
    Liang, Han
    Zheng, Zhichao
    Wang, Zhenning
    Liu, Hao
    Hu, Jiankun
    Sun, Yihong
    Zhang, Yanqiao
    Yan, Han
    Tong, Lin
    Xu, Jiahui
    Xie, Jessica
    Ji, Jiafu
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 312 - 312
  • [46] Neoadjuvant PD-1 inhibitor and apatinib combined with S-1 plus oxaliplatin for locally advanced gastric cancer patients: a multicentered, prospective, cohort study
    Xu, Chao
    Xie, Xiaoli
    Kang, Ning
    Jiang, Huiqing
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (07) : 4091 - 4099
  • [47] Neoadjuvant PD-1 inhibitor and apatinib combined with S-1 plus oxaliplatin for locally advanced gastric cancer patients: a multicentered, prospective, cohort study
    Chao Xu
    Xiaoli Xie
    Ning Kang
    Huiqing Jiang
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 4091 - 4099
  • [48] A prospective phase II clinical trial of total neoadjuvant therapy for locally advanced gastric cancer and gastroesophageal junction adenocarcinoma
    Shi, Jin-Ming
    Li, Ning
    Jiang, Li-Ming
    Yang, Lin
    Wang, Shu-Lian
    Song, Yong-Wen
    Liu, Yue-Ping
    Fang, Hui
    Lu, Ning-Ning
    Qi, Shu-Nan
    Chen, Bo
    Li, Ye-Xiong
    Zhao, Dong-Bing
    Tang, Yuan
    Jin, Jing
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [49] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Xu, Rui-hua
    Arkenau, Hendrik-Tobias
    Bang, Yung-Jue
    Denlinger, Crystal S.
    Kato, Ken
    Tabernero, Josep
    Wang, Jin
    Li, Jiang
    Castro, Henry
    Moehler, Markus H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [50] Perioperative or neoadjuvant chemotherapy for locally advanced gastric or gastroesophageal junction cancer: from independent evidence in the West, the East, and Japan to global collaboration
    Nakayama, Izuma
    Ohashi, Manabu
    Nunobe, Souya
    CHINESE CLINICAL ONCOLOGY, 2024, 13 (01)
12345